JP2024517971A - 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体 - Google Patents

放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体 Download PDF

Info

Publication number
JP2024517971A
JP2024517971A JP2023570394A JP2023570394A JP2024517971A JP 2024517971 A JP2024517971 A JP 2024517971A JP 2023570394 A JP2023570394 A JP 2023570394A JP 2023570394 A JP2023570394 A JP 2023570394A JP 2024517971 A JP2024517971 A JP 2024517971A
Authority
JP
Japan
Prior art keywords
group
acid
unit
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517971A5 (enExample
Inventor
ウェスター，ハンス－ユルゲン
パーツィンガー，マラ
ファフナー，マルクス・フレデリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of JP2024517971A publication Critical patent/JP2024517971A/ja
Publication of JP2024517971A5 publication Critical patent/JP2024517971A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023570394A 2021-05-14 2022-05-12 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体 Pending JP2024517971A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173849 2021-05-14
EP21173849.7 2021-05-14
PCT/EP2022/062985 WO2022238553A1 (en) 2021-05-14 2022-05-12 Radiopharmaceutical somatostatin receptor ligands and precursors thereof

Publications (2)

Publication Number Publication Date
JP2024517971A true JP2024517971A (ja) 2024-04-23
JP2024517971A5 JP2024517971A5 (enExample) 2025-04-15

Family

ID=75936725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570394A Pending JP2024517971A (ja) 2021-05-14 2022-05-12 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体

Country Status (11)

Country Link
US (1) US20240317780A1 (enExample)
EP (1) EP4337270A1 (enExample)
JP (1) JP2024517971A (enExample)
KR (1) KR20240008341A (enExample)
CN (1) CN117320759A (enExample)
AU (1) AU2022273184A1 (enExample)
BR (1) BR112023023890A2 (enExample)
CA (1) CA3214915A1 (enExample)
IL (1) IL308414A (enExample)
MX (1) MX2023013485A (enExample)
WO (1) WO2022238553A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117777296B (zh) * 2024-02-28 2024-05-28 北京肿瘤医院(北京大学肿瘤医院) B7h3亲和体及其诊疗核素标记物的制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019020831A1 (en) * 2017-07-28 2019-01-31 Technische Universität München AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019020831A1 (en) * 2017-07-28 2019-01-31 Technische Universität München AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM, vol. 26, JPN6026005223, 2015, pages 2350 - 2359, ISSN: 0005791491 *
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol. 326, JPN6026005222, 2020, pages 1519 - 1542, ISSN: 0005791490 *
THE JOURNAL OF NUCLEAR MEDICINE, vol. 61, no. 5, JPN6026005224, 2020, pages 735 - 742, ISSN: 0005791492 *

Also Published As

Publication number Publication date
BR112023023890A2 (pt) 2024-01-30
IL308414A (en) 2024-01-01
WO2022238553A1 (en) 2022-11-17
US20240317780A1 (en) 2024-09-26
KR20240008341A (ko) 2024-01-18
AU2022273184A1 (en) 2023-10-12
MX2023013485A (es) 2023-12-07
CA3214915A1 (en) 2022-11-17
EP4337270A1 (en) 2024-03-20
CN117320759A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
AU2024200440B2 (en) Dual mode radiotracer and -therapeutics
Failla et al. Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
CA2924360A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP2024123022A (ja) ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物
AU2022219294A9 (en) Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
JP2024517971A (ja) 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体
JP6410339B2 (ja) 放射性核種標識オクトレオチド誘導体
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
KR20220118464A (ko) 암의 영상화 및 치료법을 위한 개선된 약동학을 갖는 화합물
US20260027244A1 (en) Silicon-based fluoride acceptor groups for radiopharmaceuticals
WO2025162868A1 (en) Compounds comprising a silicon-based fluoride acceptor group useful as radiopharmceutical compounds
Floresta et al. RSC Medicinal Chemistry
EA052681B1 (ru) Лигандные соединения, содержащие хелатирующую группу в качестве мостиковой группы
JP2025532619A (ja) イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン２受容体結合分子
HK40022705A (en) Dual mode radiotracer and -therapeutics
HK40022705B (en) Dual mode radiotracer and -therapeutics
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260206